Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

DIAZEPAM PENSA 2,5 MG COMPRIMIDOS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/DIAZEPAM PENSA 2,5 MG COMPRIMIDOS

Approved

STANDARD

DIAZEPAM PENSA 2,5 MG COMPRIMIDOS

Towa Pharmaceutical S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Sep 16, 2022
Approval ID: 1324faca040e89b2
Company: Towa Pharmaceutical S.A.
Type: Standard

Approval Details

Approval Id: 1324faca040e89b2
Drug Cima Aemps Name: DIAZEPAM PENSA 2,5 MG COMPRIMIDOS
Register Number: 88092
Holder Company Name: Towa Pharmaceutical S.A.
Marketing Company Name: Towa Pharmaceutical S.A.
Authorization Date: 2022-09-16
Dosage Form: COMPRIMIDO
Dose: 2,5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica. Psicótropos
Commercialized: Yes
Company Name: Towa Pharmaceutical S.A.

Active Ingredients

DIAZEPAM

2,5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Sep 16, 2022

Approval ID

1324faca040e89b2

Type

Standard

Back to CIMA-AEMPS Approvals